| Execution period | 5 Financial years (FY 2025-26 to FY 2029-30) |
|---|
NSE filing, NSE: INVICTA. Summary written from the filing by ALFA Finder's alert engine.
Invicta Diagnostic Ltd: key numbers
- Share price
- ₹65.00
- Market cap
- ₹81.72 Cr
- Revenue (annual)
- ₹32.35 Cr
- Net profit (annual)
- ₹4.91 Cr
- P/E (TTM)
- 16.7×Sector 52.0×
- Promoter holding
- 66.70%
- FII holding
- 1.54%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Invicta Diagnostic Ltd
All →Invicta Diagnostic Management Change
Invicta Diagnostic Limited reported changes to its leadership and audit team, including a director's re-appointment, a designation change, and a new secretarial auditor.
Invicta Diagnostic Annual General Meeting
Invicta Diagnostic Limited conducted its 3rd Annual General Meeting on September 19, 2026. The proceedings detailed company operations and future financial targets.
Invicta Diagnostic Board Meeting Outcome
Board approved business outlook and forward-looking guidance for the 3rd AGM on 19 September 2026. Company targets consolidated revenue of ₹45–50 crore with ~25% EBITDA margin.
Invicta Diagnostic Capacity Expansion
Invicta's subsidiaries commenced operations at two diagnostic centres in Shegaon and Pune. Investment is Rs. 70 lakhs for CT scan and pathology services.
- diagnostic service centres
- 2 centres
Invicta Diagnostic Annual General Meeting
Invicta Diagnostic approved the notice for its 3rd Annual General Meeting scheduled for 19th September 2026, alongside adoption of financial reports and director appointments.
Invicta Diagnostic Merger & Restructuring Worth ₹0.01 Cr
Invicta Diagnostic Limited is selling its associate entity, MSCRIBEIT INFOTECH LLP, for a cash consideration of Rs. 50,000. The transaction is expected to conclude by March 2027.
- Value
- ₹0.01 Cr
Other board meeting outcome announcements
All →R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.
M K Exim (India) Board Meeting Outcome
M.K. Exim (India) approved shifting its registered office within Jaipur to Plot J-1247, Sitapura. The board meeting was held on October 28, 2026.
United Spirits Board Meeting Outcome
United Spirits' board approved amendments to its insider trading code on 28 October 2026, effective 29 October 2026. The revised code is available on the company website.
SBI Funds Management Board Meeting Outcome
SBI Funds Management extended internal auditor Chhajed & Doshi's term to March 31, 2030. This routine decision was taken at the October 28, 2026 board meeting.
- Execution
- April 1, 2028 to March 31, 2030
Paras Healthcare Board Meeting Outcome
Paras Healthcare filed its board-approved UPSI fair disclosure code under Regulation 8(2). This routine governance policy update reports no business event.
Gateway Distriparks Board Meeting Outcome
Gateway Distriparks' board approved a revised Code of Practices for Fair Disclosure of UPSI under PIT Regulation 8(2). This is a routine governance policy update with no business event.